Showing results (101-110 of 493) with videos related to
Sort By:
Pageof 50
Molecular Biotechnology|August 28, 1999
The use of soybean agglutinin (SBA) for bone marrow (BM) purging and hematopoietic progenitor cell enrichment in clinical bone-marrow transplantationA Nagler, S Morecki, S SlavinCytokines, Cellular & Molecular Therapy|January 21, 2000
Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemiaL Weiss, S Reich, S SlavinJournal of Immunology (Baltimore, Md. : 1950)|February 1, 1980
The role of the spleen in tumor growth kinetics of the murine B cell leukemia (BCL1)S Slavin, S Morecki, L WeissCancer Investigation|January 1, 1992
Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapyL Weiss, S Reich, S SlavinMagnetic Resonance in Medicine|March 31, 2005
Addressing efficiency and residual magnetization cross talk in multi-slice 2D steady-state free precession imaging of the heartGlenn S Slavin, Dan W RettmannApplied Biochemistry and Biotechnology|October 1, 1986
Depletion of human lymphocytes from peripheral blood and bone marrow by affinity ligands conjugated to agarose-polyacrolein microsphere beadsL Weiss, S Margel, S SlavinCytokines, Cellular & Molecular Therapy|January 21, 2000
Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartmentsL Weiss, S Reich, S SlavinBone Marrow Transplantation|March 1, 1990
The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrowM Mumcuoglu, E Naparstek, S SlavinAnnals of the New York Academy of Sciences|February 3, 1999
Induction of bilateral transplantation tolerance to cellular and perfused allografts and xenografts with donor hematopoietic cellsS Slavin, O Gurevitch, T PrighozinaLeukemia Research|February 1, 1996
ASTA-Z 7557 impairs human natural killer (NK) cell activityR Condiotti, S Slavin, A NaglerPageof 50